Insider Trading Alert - ENTA, REX And ARIA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, June 4, 2014, 131 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $500.01 to $4,200,565.62.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Or Yat Sun, who is Chief Scientific Officer at Enanta Pharmaceuticals, sold 5,000 shares at $37.56 on June 4, 2014. Following this transaction, the Chief Scientific Officer owned 179,078 shares meaning that the stake was reduced by 2.72% with the 5,000-share transaction.

The shares most recently traded at $39.56, up $2.00, or 5.04% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 40,000
  • 24-Week # shares sold: 801,601

The average volume for Enanta Pharmaceuticals has been 236,500 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $712.0 million and is part of the health care sector and drugs industry. Shares are up 43.88% year-to-date as of the close of trading on Wednesday.

Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. Currently, there are 3 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings rates Enanta Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that net income has been generally deteriorating over time. Get the full Enanta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

REX American Resources (REX) - FREE Research Report

Rose Stuart A, who is Cob; Ceo at REX American Resources, sold 35,000 shares at $71.83 on June 4, 2014. Following this transaction, the Cob; Ceo owned 1.1 million shares meaning that the stake was reduced by 3.08% with the 35,000-share transaction.

The shares most recently traded at $73.65, up $1.82, or 2.47% since the insider transaction. Historical insider transactions for REX American Resources go as follows:

  • 4-Week # shares sold: 40,000
  • 12-Week # shares sold: 350,693
  • 24-Week # shares sold: 540,693

The average volume for REX American Resources has been 132,300 shares per day over the past 30 days. REX American Resources has a market cap of $602.4 million and is part of the conglomerates sector and conglomerates industry. Shares are up 64.66% year-to-date as of the close of trading on Wednesday.

REX American Resources Corporation, through its subsidiaries, produces and sells ethanol. The company operates in two segments, Alternative Energy and Real Estate. The company has a P/E ratio of 11.5. Currently, there is 1 analyst who rates REX American Resources a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REX - FREE

TheStreet Quant Ratings rates REX American Resources as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full REX American Resources Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ARIAD Pharmaceuticals (ARIA) - FREE Research Report

Cantor Maria E, who is SVP, Corporate Affairs and HR at ARIAD Pharmaceuticals, sold 3,713 shares at $6.90 on June 4, 2014. Following this transaction, the SVP, Corporate Affairs and HR owned 84,461 shares meaning that the stake was reduced by 4.21% with the 3,713-share transaction.

The shares most recently traded at $6.61, down $0.29, or 4.35% since the insider transaction. Historical insider transactions for ARIAD Pharmaceuticals go as follows:

  • 12-Week # shares sold: 8,449
  • 24-Week # shares sold: 8,449

The average volume for ARIAD Pharmaceuticals has been 10.3 million shares per day over the past 30 days. ARIAD Pharmaceuticals has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are down 3.96% year-to-date as of the close of trading on Wednesday.

ARIAD Pharmaceuticals, Inc., an oncology company, is engaged in the discovery, development, and commercialization of medicines for cancer patients. Currently, there are 5 analysts who rate ARIAD Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARIA - FREE

TheStreet Quant Ratings rates ARIAD Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full ARIAD Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Steel and Aluminum Stocks Suffer Amidst Trade War Woes

Steel and Aluminum Stocks Suffer Amidst Trade War Woes

Dow Tumbles as Trump Ratchets Up China Trade Fight

Dow Tumbles as Trump Ratchets Up China Trade Fight

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target

Jim Cramer: Aramark Is a Great Company but It's Levered to Baseball

Jim Cramer: Aramark Is a Great Company but It's Levered to Baseball